Actively Recruiting
A Phase 1 Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BSY001 Injection in Healthy Adults
Led by China National Biotec Group Company Limited · Updated on 2026-01-29
76
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BSY001 for injection in healthy adults aged 18 to 50 years to assess its safety, tolerability, and how the body processes the drug. This Phase I clinical trial includes two parts a single-dose study and a multiple-dose study. The study is randomized, double-blind, and placebo-controlled to carefully monitor the effects of BSY001 compared to placebo. It is sponsored by China National Biotec Group Company Limited. The first part, BSY001-A, involves giving single ascending doses of BSY001 or placebo in five groups ranging from 37.5 mg to 300 mg. Each group receives one dose followed by blood tests and safety checks, with dosing of higher groups starting only after safety is confirmed. The second part, BSY001-B, enrolls 30 participants who receive 200 mg of BSY001 or placebo twice daily for 14 days under close hospital supervision, with regular blood sampling and safety assessments. Participants will undergo screening and then receive either BSY001 or placebo according to their group. Blood samples are collected at multiple time points to study how the drug behaves in the body. Safety is assessed through physical exams, vital signs, lab tests, electrocardiograms, and monitoring for side effects. The study lasts through dosing and follow-up periods, with detailed evaluation of drug levels and tolerability up to 20 days after dosing.
CONDITIONS
Brief Title
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.
Research Team
W
Wei Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here